Pacira BioSciences (PCRX) News Today → You missed the class - here’s your second chance (From DTI) (Ad) Free PCRX Stock Alerts $30.82 -0.69 (-2.19%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 9:07 AM | marketbeat.comFirst Eagle Investment Management LLC Has $3.48 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)First Eagle Investment Management LLC lowered its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 50.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 103,081 shares of the compMay 16 at 5:55 AM | marketbeat.comNational Bank of Canada FI Makes New Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)National Bank of Canada FI purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,200 shares of the company's stock, valued at approximaMay 14, 2024 | americanbankingnews.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Buy" by AnalystsMay 12, 2024 | americanbankingnews.comNeedham & Company LLC Lowers Pacira BioSciences (NASDAQ:PCRX) Price Target to $43.00May 12, 2024 | americanbankingnews.comPacira BioSciences (NASDAQ:PCRX) Sees Strong Trading VolumeMay 10, 2024 | markets.businessinsider.comPacira BioSciences Announces Pricing Of $250 Mln Of Convertible Senior Notes, Due 2029May 10, 2024 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Sees Unusually-High Trading VolumePacira BioSciences (NASDAQ:PCRX) Sees Strong Trading VolumeMay 10, 2024 | finance.yahoo.comEarnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their ForecastsMay 10, 2024 | americanbankingnews.comPacira BioSciences (NASDAQ:PCRX) PT Lowered to $38.00May 10, 2024 | globenewswire.comPacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029May 10, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Pacira BioSciences (NASDAQ:PCRX)May 8, 2024 | globenewswire.comPacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior NotesMay 8, 2024 | marketbeat.comPacira BioSciences' (PCRX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $57.00 price target on shares of Pacira BioSciences in a research report on Wednesday.May 8, 2024 | marketbeat.comBarclays Cuts Pacira BioSciences (NASDAQ:PCRX) Price Target to $38.00Barclays reduced their price target on shares of Pacira BioSciences from $40.00 to $38.00 and set an "overweight" rating for the company in a research report on Wednesday.May 8, 2024 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $26.51Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $26.51May 8, 2024 | finance.yahoo.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comRussell Investments Group Ltd. Sells 123,756 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Russell Investments Group Ltd. trimmed its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 35.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 226,273 shares of the company's stockMay 8, 2024 | finance.yahoo.comPacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...May 7, 2024 | investorplace.comPCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024May 7, 2024 | seekingalpha.comPacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | msn.comPacira BioSciences Non-GAAP EPS of $0.62, revenue of $167.11MMay 7, 2024 | finance.yahoo.comPacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...May 7, 2024 | globenewswire.comPacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase programMay 7, 2024 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 1, 2024 | marketbeat.comPacira BioSciences (PCRX) Set to Announce Quarterly Earnings on TuesdayPacira BioSciences (NASDAQ:PCRX) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports.April 30, 2024 | globenewswire.comPacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024April 26, 2024 | marketbeat.comWedge Capital Management L L P NC Acquires New Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)Wedge Capital Management L L P NC acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 31,414 shares of the company's stock, valued at apApril 25, 2024 | marketbeat.comabrdn plc Buys 56,081 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)abrdn plc increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 448,691 shares of the company's stock after buying an additiApril 22, 2024 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Hits New 12-Month Low at $25.74Pacira BioSciences (NASDAQ:PCRX) Sets New 1-Year Low at $25.74April 17, 2024 | nasdaq.comOversold Conditions For Pacira BioSciences (PCRX)April 16, 2024 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Up 2.7%Pacira BioSciences (NASDAQ:PCRX) Shares Up 2.7%April 15, 2024 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Sets New 52-Week Low at $25.89Pacira BioSciences (NASDAQ:PCRX) Reaches New 12-Month Low at $25.89April 11, 2024 | finance.yahoo.comPacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trendApril 11, 2024 | marketbeat.comBaillie Gifford & Co. Sells 573,810 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Baillie Gifford & Co. trimmed its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 35.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,063,266 shares of the company's stock after selliApril 9, 2024 | markets.businessinsider.comUnderstanding Key Factors Behind Pacira Pharmaceuticals’ Analyst RatingApril 9, 2024 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $45.00 price target on shares of Pacira BioSciences in a report on Tuesday.April 6, 2024 | nasdaq.comCommit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using OptionsApril 2, 2024 | globenewswire.comPacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 30, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Assenagon Asset Management S.A.Assenagon Asset Management S.A. raised its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 185.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 246,621 shares of the company's stockMarch 29, 2024 | marketbeat.comGradient Investments LLC Increases Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Gradient Investments LLC raised its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 33.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,949 shares of the company's stock afMarch 26, 2024 | marketbeat.comTributary Capital Management LLC Raises Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Tributary Capital Management LLC raised its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 32.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 242,005 shares of the company'sMarch 25, 2024 | marketbeat.comWellington Management Group LLP Lowers Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)Wellington Management Group LLP reduced its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 28.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 313,910 shaMarch 22, 2024 | marketbeat.comDeutsche Bank AG Has $5.60 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Deutsche Bank AG trimmed its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 22.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 182,399 shares of the company's stock after selling 51,March 18, 2024 | insidertrades.comGary W. Pace Sells 1,066 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockMarch 16, 2024 | finance.yahoo.comPCRX Apr 2024 22.500 putMarch 13, 2024 | marketwatch.comPacira's PCRX-201 Gets FDA RMAT Designation in Knee OsteoarthritisMarch 13, 2024 | markets.businessinsider.comPacira BioSciences Receives RMAT Designation For Gene Therapy Product Candidate In OsteoarthritisMarch 13, 2024 | globenewswire.comPacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneeMarch 11, 2024 | insidertrades.comPacira BioSciences, Inc. (NASDAQ:PCRX) Director Sells $2,754,000.00 in StockMarch 10, 2024 | marketbeat.comSchroder Investment Management Group Cuts Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)Schroder Investment Management Group trimmed its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 20.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 667,628 shares of the company's stock after selling 171,307 shares during Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Free report reveals “two-baggers” for 2024 (Ad)We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable. Download your free report today! PCRX Media Mentions By Week PCRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCRX News Sentiment▼0.930.42▲Average Medical News Sentiment PCRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCRX Articles This Week▼33▲PCRX Articles Average Week Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Supernus Pharmaceuticals News Today Agios Pharmaceuticals News Today OPKO Health News Today ALX Oncology News Today Atea Pharmaceuticals News Today ADC Therapeutics News Today Nektar Therapeutics News Today Seres Therapeutics News Today Corcept Therapeutics News Today Perrigo News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
